Emerging infection: streptococcal toxic shock-like syndrome caused by group B Streptococcus (GBS), Streptococcus agalactiae
DOI:
https://doi.org/10.4322/acr.2024.497Keywords:
Amputation, Surgical, Bacteremia, Fasciitis, Necrotizing, Shock, Septic, Virulence FactorsAbstract
Streptococcus agalactiae or Group B Streptococcus (GBS) infections are commonly associated with infections in neonates and pregnant women. However, there has been a rising incidence in nonpregnant adults. The risk of GBS infection in nonpregnant adults is increased for patients of advanced age and those with underlying medical conditions such as diabetes mellitus and cancer. We present a 77-year-old female with type-2 diabetes mellitus, hypertension, and bilateral foot ulcers that presented in probable septic shock with necrotic foot ulcers and necrotizing fasciitis and underwent bilateral lower limb amputations. The patient fulfilled the Streptococcal Toxic Shock Syndrome (STSS) criteria as defined by The Working Group on Severe Streptococcal Infections. These criteria were created for group A Streptococcus (Streptococcus pyogenes). Our patient fulfilled the Working Group’s criteria, except that the blood culture was positive for group B Streptococcus (Streptococcus agalactiae). Numerous studies demonstrate the importance of early detection and antibiotic treatment for GBS infections in general and early surgical management for necrotizing soft tissue infections (NSTIs) such as necrotizing fasciitis.
Downloads
References
Bobadilla FJ, Novosak MG, Cortese IJ, Delgado OD, Laczeski ME. Prevalence, serotypes and virulence genes of Streptococcus agalactiae isolated from pregnant women with 35-37 weeks of gestation. BMC Infect Dis. 2021;21(1):73. http://doi.org/10.1186/s12879-020-05603-5. PMid:33446117.
Filkins L, Hauser JR, Robinson-Dunn B, Tibbetts R, Boyanton BL, Revell P. American Society for Microbiology Provides 2020 Guidelines for Detection and Identification of Group B Streptococcus. J Clin Microbiol. 2020;59(1):e01230-20. http://doi.org/10.1128/JCM.01230-20. PMid:33115849.
Baker CJ, Barrett FF. Group B streptococcal infections in infants. The importance of the various serotypes. JAMA. 1974;230(8):1158-60. http://doi.org/10.1001/jama.1974.03240080040025. PMid:4608888.
Horn KA, Group B. Streptococcal neonatal infection. JAMA. 1974;230(8):1165-7. http://doi.org/10.1001/jama.1974.03240080047029. PMid:4608889.
Russell NJ, Seale AC, O’Driscoll M, et al. Maternal colonization with Group B streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(Suppl 2):S100-11. http://doi.org/10.1093/cid/cix658. PMid:29117327.
Lawn JE, Bianchi-Jassir F, Russell NJ, et al. Streptococcal disease worldwide for pregnant women, stillbirths, and children: why, what, and how to undertake estimates? Clin Infect Dis. 2017;65(Suppl 2):S89-99. http://doi.org/10.1093/cid/cix653. PMid:29117323.
Sendi P, Johansson L, Norrby-Teglund A. Invasive group B Streptococcal disease in nonpregnant adults : a review with emphasis on skin and soft-tissue infections. Infection. 2008;36(2):100-11. http://doi.org/10.1007/s15010-007-7251-0. PMid:18193384.
Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000;342(1):15-20. http://doi.org/10.1056/NEJM200001063420103. PMid:10620644.
Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ. 1992;41(6):25-32. PMid:1470102.
Nanduri SA, Petit S, Smelser C, et al. Epidemiology of invasive early-onset and late-onset Group B streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance. JAMA Pediatr. 2019;173(3):224-33. http://doi.org/10.1001/jamapediatrics.2018.4826. PMid:30640366.
Al Akhrass F, Abdallah L, Berger S, et al. Streptococcus agalactiae toxic shock-like syndrome: two case reports and review of the literature. Medicine (Baltimore). 2013;92(1):10-4. http://doi.org/10.1097/MD.0b013e31827dea11. PMid:23263717.
Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis. 2009;49(1):85-92. http://doi.org/10.1086/599369. PMid:19480572.
Francois Watkins LK, McGee L, Schrag SJ, et al. Epidemiology of invasive Group B streptococcal infections among nonpregnant adults in the United States, 2008-2016. JAMA Intern Med. 2019;179(4):479-88. http://doi.org/10.1001/jamainternmed.2018.7269. PMid:30776079.
Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Group A Streptococcus, 2016. USA: CDC; 2018 [cited 2023 Sep 26]. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/gas16.pdf
Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance (ABCs). Report Emerging Infections Program Network Streptococcus pneumoniae, 2016. USA: CDC; 2018 [cited 2023 Sep 26]. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu16.pdf
Muñoz P, Llancaqueo A, Rodríguez-Créixems M, Peláez T, Martin L, Bouza E. Group B streptococcus bacteremia in nonpregnant adults. Arch Intern Med. 1997;157(2):213-6. http://doi.org/10.1001/archinte.1997.00440230087011. PMid:9009979.
Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis. 2001;33(4):556-61. http://doi.org/10.1086/322696. PMid:11462195.
Farley MM, Harvey RC, Stull T, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med. 1993;328(25):1807-11. http://doi.org/10.1056/NEJM199306243282503. PMid:8502269.
Schwartz B, Schuchat A, Oxtoby MJ, Cochi SL, Hightower A, Broome CV. Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA. 1991;266(8):1112-4. http://doi.org/10.1001/jama.1991.03470080082034. PMid:1865545.
Harrison LH, Ali A, Dwyer DM, et al. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med. 1995;123(6):421-7. http://doi.org/10.7326/0003-4819-123-6-199509150-00004. PMid:7639441.
Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 2008;299(17):2056-65. http://doi.org/10.1001/jama.299.17.2056. PMid:18460666.
Jackson LA, Hilsdon R, Farley MM, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med. 1995;123(6):415-20. http://doi.org/10.7326/0003-4819-123-6-199509150-00003. PMid:7639440.
Manning SD, Tallman P, Baker CJ, Gillespie B, Marrs CF, Foxman B. Determinants of co-colonization with group B streptococcus among heterosexual college couples. Epidemiology. 2002;13(5):533-9. http://doi.org/10.1097/00001648-200209000-00008. PMid:12192222.
Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978;312(8100):1116-8. http://doi.org/10.1016/S0140-6736(78)92274-2. PMid:82681.
Hansen NS, Leth S, Nielsen LT. Toxic shock syndrome. Ugeskr Laeger. 2020;182(20):V11190673. PMid:32400378.
Silversides JA, Lappin E, Ferguson AJ. Staphylococcal toxic shock syndrome: mechanisms and management. Curr Infect Dis Rep. 2010;12(5):392-400. http://doi.org/10.1007/s11908-010-0119-y. PMid:21308522.
Burnham JP, Kollef MH. Understanding toxic shock syndrome. Intensive Care Med. 2015;41(9):1707-10. http://doi.org/10.1007/s00134-015-3861-7. PMid:25971393.
Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, Perkins BA. Toxic shock syndrome in the United States: surveillance update, 1979 1996. Emerg Infect Dis. 1999;5(6):807-10. http://doi.org/10.3201/eid0506.990611. PMid:10603216.
Venkataraman R. Toxic Shock Syndrome. Newark: Medscape; 2023 [cited 2023 Sep 26]. Available from: https://emedicine.medscape.com/article/169177-overview
Javid Khojasteh V, Rogan MT, Edwards-Jones V, Foster HA. Detection of antibodies to Staphylococcus aureus Toxic Shock Syndrome Toxin-1 using a competitive agglutination inhibition assay. Lett Appl Microbiol. 2003;36(6):372-6. http://doi.org/10.1046/j.1472-765X.2003.01330.x. PMid:12753244.
Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987;317(3):146-9. http://doi.org/10.1056/NEJM198707163170305. PMid:3299086.
Breiman RF. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA. 1993;269(3):390-1. http://doi.org/10.1001/jama.1993.03500030088038. PMid:8418347.
Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321(1):1-7. http://doi.org/10.1056/NEJM198907063210101. PMid:2659990.
Khan Z. Group A Streptococcal (GAS) Infections. Newark: Medscape; 2023 [cited 2023 Sep 26]. Available from: https://emedicine.medscape.com/article/228936-overview
Balk RA. SIRS, Sepsis, and Septic Shock Criteria. [place unknown]: MDCalc; 2023 [cited 2023 Sep 26]. Available from: https://www.mdcalc.com/calc/1096/sirs-sepsis-septic-shock-criteria
Wang YS, Wong CH, Tay YK. Staging of necrotizing fasciitis based on the evolving cutaneous features. Int J Dermatol. 2007;46(10):1036-41. http://doi.org/10.1111/j.1365-4632.2007.03201.x. PMid:17910710.
Bakleh M, Wold LE, Mandrekar JN, Harmsen WS, Dimashkieh HH, Baddour LM. Correlation of histopathologic findings with clinical outcome in necrotizing fasciitis. Clin Infect Dis. 2005;40(3):410-4. http://doi.org/10.1086/427286. PMid:15668865.
Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis. 2005;41(6):839-47. http://doi.org/10.1086/432804. PMid:16107984.
Amaya RA, Baker CJ, Keitel WA, Edwards MS. Healthy elderly people lack neutrophil-mediated functional activity to type V group B Streptococcus. J Am Geriatr Soc. 2004;52(1):46-50. http://doi.org/10.1111/j.1532-5415.2004.52009.x. PMid:14687314.
Palazzi DL, Rench MA, Edwards MS, Baker CJ. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis. 2004;190(3):558-64. http://doi.org/10.1086/422010. PMid:15243932.
Baker CJ, Webb BJ, Kasper DL, Edwards MS. The role of complement and antibody in opsonophagocytosis of type II group B streptococci. J Infect Dis. 1986;154(1):47-54. http://doi.org/10.1093/infdis/154.1.47. PMid:3519791.
Mazade MA, Edwards MS. Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab. 2001;73(3):259-67. http://doi.org/10.1006/mgme.2001.3185. PMid:11461193.
Tang WM, Ho PL, Yau WP, Wong JW, Yip DK. Report of 2 fatal cases of adult necrotizing fasciitis and toxic shock syndrome caused by Streptococcus agalactiae. Clin Infect Dis. 2000;31(4):E15-7. http://doi.org/10.1086/318148. PMid:11049806.
Tyrrell GJ, Senzilet LD, Spika JS, et al. Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit Surveillance System Site Coordinators. J Infect Dis. 2000;182(1):168-73. http://doi.org/10.1086/315699. PMid:10882594.
Fukuda K, Ryujin M, Sakio R, Fukuzumi S, Omae T, Hayakawa K. Bilateral necrotizing fasciitis of the foot associated with Group B streptococcus. Case Rep Dermatol. 2016;8(3):243-9. http://doi.org/10.1159/000448163. PMid:27790114.
Centers for Disease Control and Prevention [Internet]. Streptococcus Laboratory: Streptococcus agalactiae. USA: CDC; 2023 [cited 2023 Sep 26]. Available from: https://www.cdc.gov/streplab/groupb-strep/index.html
Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 1981;68(4):544-9. http://doi.org/10.1542/peds.68.4.544. PMid:7033911.
Umemura H, Hiragushi K, Sasaki S, et al. A male with group B streptococcal necrotizing fasciitis at multiple sites secondary to multifocal septic arthritis. Acta Derm Venereol. 2015;95(5):614-5. http://doi.org/10.2340/00015555-2015. PMid:25403478.
Sendi P, Johansson L, Dahesh S, et al. Bacterial phenotype variants in group B streptococcal toxic shock syndrome. Emerg Infect Dis. 2009;15(2):223-32. http://doi.org/10.3201/eid1502.080990. PMid:19193266.
Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun. 1992;60(10):3986-93. http://doi.org/10.1128/iai.60.10.3986-3993.1992. PMid:1398910.
Puliti M, Nizet V, von Hunolstein C, et al. Severity of group B streptococcal arthritis is correlated with beta-hemolysin expression. J Infect Dis. 2000;182(3):824-32. http://doi.org/10.1086/315773. PMid:10950777.
Cornacchione P, Scaringi L, Fettucciari K, et al. Group B streptococci persist inside macrophages. Immunology. 1998;93(1):86-95. http://doi.org/10.1046/j.1365-2567.1998.00402.x. PMid:9536123.
Liu GY, Doran KS, Lawrence T, et al. Sword and shield: linked group B streptococcal beta-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense. Proc Natl Acad Sci USA. 2004;101(40):14491-6. http://doi.org/10.1073/pnas.0406143101. PMid:15381763.
Souza VC, Kegele FC, Souza SR, Neves FP, de Paula GR, Barros RR. Antimicrobial susceptibility and genetic diversity of Streptococcus agalactiae recovered from newborns and pregnant women in Brazil. Scand J Infect Dis. 2013;45(10):780-5. http://doi.org/10.3109/00365548.2013.810814. PMid:23876189.
Larsson C, Lindroth M, Nordin P, Stålhammar-Carlemalm M, Lindahl G, Krantz I. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed. 2006;91(6):F403-8. http://doi.org/10.1136/adc.2005.090472. PMid:17056838.
Lindahl G, Akerström B, Vaerman JP, Stenberg L. Characterization of an IgA receptor from group B streptococci: specificity for serum IgA. Eur J Immunol. 1990;20(10):2241-7. http://doi.org/10.1002/eji.1830201013. PMid:2242758.
Pleass RJ, Areschoug T, Lindahl G, Woof JM. Streptococcal IgA-binding proteins bind in the Calpha 2-Calpha 3 interdomain region and inhibit binding of IgA to human CD89. J Biol Chem. 2001;276(11):8197-204. http://doi.org/10.1074/jbc.M009396200. PMid:11096107.
Pietrocola G, Visai L, Valtulina V, et al. Multiple interactions of FbsA, a surface protein from Streptococcus agalactiae, with fibrinogen: affinity, stoichiometry, and structural characterization. Biochemistry. 2006;45(42):12840-52. http://doi.org/10.1021/bi060696u. PMid:17042502.
Schubert A, Zakikhany K, Pietrocola G, et al. The fibrinogen receptor FbsA promotes adherence of Streptococcus agalactiae to human epithelial cells. Infect Immun. 2004;72(11):6197-205. http://doi.org/10.1128/IAI.72.11.6197-6205.2004. PMid:15501744.
Lindahl G, Stålhammar-Carlemalm M, Areschoug T. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev. 2005;18(1):102-27. http://doi.org/10.1128/CMR.18.1.102-127.2005. PMid:15653821.
Madoff LC, Michel JL, Gong EW, Kling DE, Kasper DL. Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci USA. 1996;93(9):4131-6. http://doi.org/10.1073/pnas.93.9.4131. PMid:8633028.
Luan SL, Granlund M, Sellin M, Lagergård T, Spratt BG, Norgren M. Multilocus sequence typing of Swedish invasive group B streptococcus isolates indicates a neonatally associated genetic lineage and capsule switching. J Clin Microbiol. 2005;43(8):3727-33. http://doi.org/10.1128/JCM.43.8.3727-3733.2005. PMid:16081902.
Cornacchione P, Scaringi L, Fettucciari K, et al. Group B streptococci persist inside macrophages. Immunology. 1998;93(1):86-95. http://doi.org/10.1046/j.1365-2567.1998.00402.x. PMid:9536123.
Nawijn F, Smeeing DPJ, Houwert RM, Leenen LPH, Hietbrink F. Time is of the essence when treating necrotizing soft tissue infections: a systematic review and meta-analysis. World J Emerg Surg. 2020;15(1):4. http://doi.org/10.1186/s13017-019-0286-6. PMid:31921330.
Gelbard RB, Ferrada P, Yeh DD, et al. Optimal timing of initial debridement for necrotizing soft tissue infection: a Practice Management Guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2018;85(1):208-14. http://doi.org/10.1097/TA.0000000000001857. PMid:29485428.
Berner R. Group B streptococcus vaccines: one step further. Lancet Infect Dis. 2021;21(2):158-60. http://doi.org/10.1016/S1473-3099(20)30451-5. PMid:32891192.
Carreras-Abad C, Ramkhelawon L, Heath PT, Le Doare K. A vaccine against Group B Streptococcus: recent advances. Infect Drug Resist. 2020;13:1263-72. http://doi.org/10.2147/IDR.S203454. PMid:32425562.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Fareed Rajack, Shawn Medford, Ali Ramadan, Tammey Naab
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
Authors of articles published by Autopsy and Case Report retain the copyright of their work without restrictions, licensing it under the Creative Commons Attribution License - CC-BY, which allows articles to be re-used and re-distributed without restriction, as long as the original work is correctly cited.
